| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2019 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS INC | 3 | Q2 2024 | 23.9% |
| ARGENX SE | 3 | Q2 2024 | 21.6% |
| AXSOME THERAPEUTICS INC | 3 | Q2 2024 | 14.1% |
| CYTOKINETICS INC | 3 | Q2 2024 | 11.6% |
| PROTAGONIST THERAPEUTICS INC | 3 | Q2 2024 | 7.4% |
| PHATHOM PHARMACEUTICALS INC | 3 | Q2 2024 | 5.4% |
| ATYR PHARMA INC | 3 | Q2 2024 | 1.9% |
| TREVI THERAPEUTICS INC | 3 | Q2 2024 | 1.2% |
| ALLAKOS INC | 3 | Q2 2024 | 0.7% |
| AVADEL PHARMACEUTICALS PLC | 2 | Q1 2024 | 7.9% |
View Checkpoint Capital L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2023-06-15 |
| SC 13G | 2023-06-12 |
View Checkpoint Capital L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.